These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 1666360

  • 1. Cross-resistance and cross-susceptibility between fluoroquinolone agents.
    Barry AL, Fuchs PC.
    Eur J Clin Microbiol Infect Dis; 1991 Dec; 10(12):1013-8. PubMed ID: 1666360
    [Abstract] [Full Text] [Related]

  • 2. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
    Naber KG, Well M, Hollauer K, Kirchbauer D, Witte W.
    Chemotherapy; 1998 Dec; 44(2):77-84. PubMed ID: 9551236
    [Abstract] [Full Text] [Related]

  • 3. Selection of a fluoroquinolone-class disk for susceptibility tests.
    Barry AL, Fuchs PC.
    Am J Med; 1993 Mar 22; 94(3A):17S-22S. PubMed ID: 8383918
    [Abstract] [Full Text] [Related]

  • 4. A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: an interim report from 27 centers.
    Beskid G, Prosser BL.
    Am J Med; 1993 Mar 22; 94(3A):2S-8S. PubMed ID: 8383919
    [Abstract] [Full Text] [Related]

  • 5. In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents.
    Barry AL, Jones RN.
    J Antimicrob Chemother; 1989 Apr 22; 23(4):527-35. PubMed ID: 2745259
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).
    Cormican MG, Marshall SA, Jones RN.
    Diagn Microbiol Infect Dis; 1995 Jan 22; 21(1):51-4. PubMed ID: 7789097
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Detection of quinolone-resistant Neisseria gonorrhoeae.
    Kam KM, Wong PW, Cheung MM, Ho NK.
    J Clin Microbiol; 1996 Jun 22; 34(6):1462-4. PubMed ID: 8735098
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In vitro activity of CP-74667 compared with four other fluoroquinolones.
    Jones RN, Erwin ME.
    Diagn Microbiol Infect Dis; 1992 Aug 22; 15(6):531-6. PubMed ID: 1330419
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin.
    Knapp JS, Hale JA, Neal SW, Wintersheid K, Rice RJ, Whittington WL.
    Antimicrob Agents Chemother; 1995 Nov 22; 39(11):2442-5. PubMed ID: 8585723
    [Abstract] [Full Text] [Related]

  • 20. The in-vitro activity of temafloxacin compared with other antimicrobial agents.
    King A, Bethune L, Phillips I.
    J Antimicrob Chemother; 1991 Jun 22; 27(6):769-79. PubMed ID: 1657855
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.